TY - JOUR
T1 - Sigma-1 receptor and seizures
AU - Vavers, Edijs
AU - Zvejniece, Liga
AU - Dambrova, Maija
N1 - Funding Information:
This review article was supported by the European Regional Development Fund Project No. 1.1.1.2/VIAA/2/18/376 "Sigma chaperone protein as a novel drug target". Authors were supported by the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 857394 . EV would like to thank Jolanta Jonane for helping with the tables and references.
Funding Information:
This review article was supported by the European Regional Development Fund Project No. 1.1.1.2/VIAA/2/18/376 "Sigma chaperone protein as a novel drug target". Authors were supported by the European Union's Horizon 2020 research and innovation programme under grant agreement No. 857394. EV would like to thank Jolanta Jonane for helping with the tables and references.
Publisher Copyright:
© 2023 The Authors
PY - 2023/5
Y1 - 2023/5
N2 - Over the last decade, sigma-1 receptor (Sig1R) has been recognized as a valid target for the treatment of seizure disorders and seizure-related comorbidities. Clinical trials with Sig1R ligands are underway testing therapies for the treatment of drug-resistant seizures, developmental and epileptic encephalopathies, and photosensitive epilepsy. However, the direct molecular mechanism by which Sig1R modulates seizures and the balance between excitatory and inhibitory pathways has not been fully elucidated. This review article aims to summarize existing knowledge of Sig1R and its involvement in seizures by focusing on the evidence obtained from Sig1R knockout animals and the anti-seizure effects of Sig1R ligands. In addition, this review article includes a discussion of the advantages and disadvantages of the use of existing compounds and describes the challenges and future perspectives on the use of Sig1R as a target for the treatment of seizure disorders.
AB - Over the last decade, sigma-1 receptor (Sig1R) has been recognized as a valid target for the treatment of seizure disorders and seizure-related comorbidities. Clinical trials with Sig1R ligands are underway testing therapies for the treatment of drug-resistant seizures, developmental and epileptic encephalopathies, and photosensitive epilepsy. However, the direct molecular mechanism by which Sig1R modulates seizures and the balance between excitatory and inhibitory pathways has not been fully elucidated. This review article aims to summarize existing knowledge of Sig1R and its involvement in seizures by focusing on the evidence obtained from Sig1R knockout animals and the anti-seizure effects of Sig1R ligands. In addition, this review article includes a discussion of the advantages and disadvantages of the use of existing compounds and describes the challenges and future perspectives on the use of Sig1R as a target for the treatment of seizure disorders.
UR - https://www-webofscience-com.db.rsu.lv/wos/alldb/full-record/MEDLINE:37068533
UR - https://www.scopus.com/pages/publications/85152907541
U2 - 10.1016/j.phrs.2023.106771
DO - 10.1016/j.phrs.2023.106771
M3 - Review article
C2 - 37068533
SN - 1043-6618
VL - 191
JO - Pharmacological Research
JF - Pharmacological Research
M1 - 106771
ER -